1 paper2 findings
Risk discrimination for CKM progression
upin humans1
TyG-NCCR improves risk discrimination for CKM progression in humans.
Humanscompared with TyG and TG/HDL-C5 and 8 years
Combined blood marker linked to cardiovascular disease risk
Cardiovascular diabetology9 Oct 2026
Progression to CKM stage 4
upin humans1HR 1.2
TyG-NCCR predicts progression to CKM stage 4 in humans (HR 1.20 per SD increase, 95% CI 1.13–1.29).
HumansCHARLS participants with CKM stages 0–3 at baseline; adjusted Cox modelseach SD increase2011 to 2020n = 5,474
Combined blood marker linked to cardiovascular disease risk
Cardiovascular diabetology9 Oct 2026
An observational study followed 5,474 Chinese participants from 2011 to 2020 and linked higher marker values to progression to clinical cardiovascular disease.An observational study followed 5,474 Chinese participants from 2011 to 2020 and linked higher marker values to progression to clinical cardiovascular disease.